Stereochemistry | ABSOLUTE |
Molecular Formula | C19H21NO2 |
Molecular Weight | 295.3755 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC3=CC=CC=C3C4=C(OC)C(OC)=CC(CCN1C)=C24
InChI
InChIKey=ORJVQPIHKOARKV-OAHLLOKOSA-N
InChI=1S/C19H21NO2/c1-20-9-8-13-11-16(21-2)19(22-3)18-14-7-5-4-6-12(14)10-15(20)17(13)18/h4-7,11,15H,8-10H2,1-3H3/t15-/m1/s1
Molecular Formula | C19H21NO2 |
Molecular Weight | 295.3755 |
Charge | 0 |
Count |
MOL RATIO
1 MOL RATIO (average) |
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. Nuciferine was studied as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels. In addition, was suggested, that nuciferine had atypical antipsychotic-like actions. Nuciferine was an antagonist at 5-HT2A, 5-HT2C, and 5-HT2B, an inverse agonist at 5-HT7, a partial agonist at D2, D5 and 5-HT6, an agonist at 5-HT1A and D4 receptors, and inhibited the dopamine transporter. In addition, was shown, that that nuciferine had a therapeutic effect on respiratory diseases associated with the aberrant contraction of airway smooth muscles and/or bronchospasm through the blockade of voltage-dependent L-type Ca2+ channels and/or nonselective cation channels.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
tumor-bearing mice: Mice in the nuciferine (1) group were immediately administered nuciferine (ip) after tumor implantation, and mice in the nuciferine (2) group were administered nuciferine (ip) when the tumor xenografts reached a size of 100 mm3. Mice in the nuciferine (1) group and nuciferine (2) group were administered nuciferine (ip) three times a week at a dosage of 9.5 mg/kg.
Route of Administration:
Oral